Table 1.
Baseline patient characteristics.
| Parameter | Wringing rotation Group A |
Rigid-body-type rotation Group B |
p value |
|---|---|---|---|
| Age (years) | 70.5 ± 3.8 | 64.2 ± 5.9 | 0.02 |
| Male, n (%) | 3 (50) | 18 (75) | 0.30 |
| ECG characteristics | |||
| QRS duration (ms) | 170 ± 29 | 168 ± 16 | 0.80 |
| LBBB morphology, n (%) | 6 (100) | 24 (100) | 1.0 |
| NYHA functional class | |||
| II, n (%) | 4 (66.7) | 12 (50) | 0.37 |
| III, n (%) | 2 (33.3) | 12 (54.5) | 0.37 |
| HF etiology | |||
| Ischemic, n (%) | 6 (100) | 24 (100) | 1.0 |
| Medications, n (%) | |||
| ACE-Is/ARBs | 6 (100) | 24 (100) | 1.0 |
| Beta-blockers | 6 (100) | 24 (100) | 1.0 |
| Diuretics and/or spironolactone | 6 (100) | 23 (95.8) | 1.0 |
| LVEDV (ml) | 247.0 ± 106.8 | 238.9 ± 54.4 | 0.79 |
| LVESV (ml) | 181.5 ± 80.8 | 177.6 ± 40.8 | 0.87 |
| LVEF (%) | 27.0 ± 10.0 | 25.7 ± 5.0 | 0.65 |
| Sphericity index | 1.65 ± 0.13 | 1.59 ± 0.16 | 0.42 |
Values are mean ± SD, median (25th; 75th percentile) or n (%).
ACE-I angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blocker, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end-systolic volume, LVEF left ventricle ejection fraction.